Recent Updates — NSRX
On October 8, 2026, shareholders of Nasus Pharma Ltd. convened an Annual and Special General Meeting where all agenda items were approved by the required majority except for Proposal No. 4. The specific details of the rejected proposal are contained in the company's prior proxy statement filed on September 4, 2026. Nasus Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases.
On September 18, 2026, Nasus Pharma Ltd. entered into an At-The-Market Sales Agreement with BTIG, LLC to offer and sell ordinary shares from time to time as agent under its effective Form F-3 registration statement. The company is not obligated to sell any specific amount of shares but intends to use net proceeds for the ongoing clinical development of NS002 for anaphylaxis treatment, initiating studies for other pipeline products, and working capital. The sales agent receives a commission of up to 3.0% of aggregate gross proceeds. Nasus Pharma Ltd. operates in the biopharmaceutical industry, focusing on drug discovery and development.
On September 14, 2026, Nasus Pharma Ltd. announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for NS002, an investigational intranasal epinephrine powder designed as a needle-free alternative to EpiPen for treating anaphylaxis. The company plans to initiate a pivotal clinical study in the fourth quarter of 2026, with top-line data readout anticipated in the first quarter of 2027. This regulatory milestone advances NS002 toward commercialization in a market currently dominated by injectable autoinjectors. Nasus Pharma Ltd. is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary powder technology platform.
Nasus Pharma Ltd. announced the resignation of Chief Financial Officer Eyal Rubin, effective September 18, 2026, to pursue opportunities outside the life science industry. The departure was not related to any disagreements regarding operations or policies. Oren Elmaliach, currently serving as Director of Finance, has been appointed interim Chief Financial Officer to ensure continuity during the transition period. Nasus Pharma Ltd. is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary powder technology platform.
Nasus Pharma Ltd. reported a net loss of $5.9 million for the six months ended June 30, 2026, compared to a $1.3 million loss in the prior year period. The company raised $15.0 million in gross proceeds from a private placement completed on February 13, 2026, bringing its cash and short-term deposits to approximately $11.9 million as of June 30, 2026. Management appointed Brendan O’Grady as Chief Executive Officer effective July 27, 2026. Clinically, the company plans to initiate a pivotal Phase 3 study for its lead candidate NS002 (intranasal epinephrine) in the fourth quarter of 2026 and expects to begin first-in-human trials for NS003 (ondansetron) shortly. The filing includes unaudited interim financial statements, management discussion, and a press release detailing these results and updates. Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on developing innovative intranasal powder-based therapies.